Tag: PAD
Data and device tweaks herald ‘practice-changing’ future for bioabsorbable scaffolds
Pending the results of several trials and “iterative changes” to device design, bioabsorbable sc...
Study finds adverse outcomes after decreased use of paclitaxel-coated devices
A recent analysis of over 270,000 Medicare fee-for-service beneficiaries has found an increase i...
Two-year LIFE-BTK data show sustained benefits of drug-eluting resorbable scaffold for below-the-knee arteries
Presented today, late-breaking data from the second year of the LIFE-BTK clinical trial demonstr...
New ESC guidelines combine peripheral arterial and aortic diseases for first time, emphasising interconnectivity of whole arterial system
The European Society of Cardiology (ESC) has today published its 2024 guidelines for the management ...
CX 2024: Paclitaxel device restrictions “did cause harm”
“Unfortunately, we are doing worse for our patients today,” were the sobering words of Eric Sece...
SCAI, SIR, SVS jointly publish proceedings from multispecialty peripheral IVUS roundtable
Proceedings from an expert consensus roundtable that discussed the benefits of intravascular ult...
TCT 2023: First presentation of complete patient-level dataset on paclitaxel and death that helped sway the US FDA
Data from a patient-level meta-analysis—a factor in the US Food and Drug Administration’s (FDA) ...
Boston Scientific announces position on FDA update about use of paclitaxel-coated devices to treat PAD
Following yesterday's news that the US Food and Drug Administration (FDA) has changed its stance on ...
Long-awaited US FDA update finds data do not support excess mortality risk for paclitaxel-coated devices
In a letter to healthcare providers dated 11 July 2023, the US Food and Drug Administration (FDA...
Black patients nearly 50% less likely to receive revascularisation for PAD
A new study from Keck Medicine at the University of Southern California (USC; Los Angeles, USA) ...
BASIL-2 points towards endovascular-first revascularisation strategy in CLTI patients
A question from Manj Gohel (Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK) on w...
New VOYAGER PAD analysis confirms consistent benefit of low-dose rivaroxaban plus aspirin following lower extremity revascularisation
Data from a new prespecified analysis of the phase III VOYAGER PAD clinical trial show that low-...
Cardiovascular Systems announces development of IVL technology for the treatment of coronary and peripheral arterial diseases
Cardiovascular Systems recently announced that it has made significant progress towards the commerci...
VIVA 2021: Consensus established for appropriate use of IVUS in peripheral interventions
A worldwide committee of 40 cross-specialty medical experts achieved the first-ever consensus fo...
First patient treated with Cardiovascular Systems’ ViperCross peripheral support catheter
Cardiovascular Systems recently announced that the first patient has been successfully treated with ...
ACC 2021: VOYAGER-PAD analysis shows totality of ischaemic events reduced following rivaroxaban use
Rupert Bauersachs (Darmstadt, Germany) talks to Cardiovascular News about the VOYAGER-PAD trial,...
Customising therapy in femoropopliteal revascularisation
Gary Ansel (Columbus, USA) tells Vascular News at VEITHSymposium 2018 about how drug-based ther...
